Feedback
Settings

Settings

Goto Application

1. WO2021011327 - COMPOUND FOR TREATING CYSTIC FIBROSIS

Submit observation
PermaLink
Publication Number WO/2021/011327
Publication Date 21.01.2021
International Application No. PCT/US2020/041490
International Filing Date 10.07.2020
IPC
A61K 31/357 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
357having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/4025 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
4025not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/404 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403condensed with carbocyclic rings, e.g. carbazole
404Indoles, e.g. pindolol
CPC
A61K 31/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
A61K 9/0053
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0053Mouth and digestive tract, i.e. intraoral and peroral administration
A61K 9/20
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, tablets, ; discs, rods
C07D 401/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
Applicants
  • ORPHOMED, INC. [US]/[US]
Inventors
  • SINGH, Nikhilesh Nihala
Agents
  • KEZER, William B.
  • TRIMBLE, Alexander R.
  • DOLAN, Gregory F.
  • DONG, Yaohua
Priority Data
62/873,55612.07.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) COMPOUND FOR TREATING CYSTIC FIBROSIS
(FR) COMPOSÉ POUR LE TRAITEMENT DE LA FIBROSE KYSTIQUE
front page image
Abstract
(EN)
Provided herein is a compound represented by Formula I: (I) or a pharmaceutically acceptable salt, hydrate, solvate or complex thereof. Also provided are pharmaceutical compositions comprising the compound noted above, in combination with a pharmaceutically acceptable excipient.
(FR)
L'invention concerne un composé représenté par la formule I : (I) ou un sel pharmaceutiquement acceptable, un hydrate, un solvate ou un complexe de celui-ci. L'invention concerne également des compositions pharmaceutiques comprenant le composé susmentionné, en association avec un excipient pharmaceutiquement acceptable.
Latest bibliographic data on file with the International Bureau
# -